Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fabre-Kramer Pharmaceuticals
Private drug developer Fabre-Kramer is expecting approval for its antidepressant gepirone hydrochloride in September 2023. The drug has been rejected multiple times by the FDA as a treatment for major depressive disorder.
US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month
Two gene therapies and two novel inhibitors of JAK kinases are among the upcoming goal dates from the Pink Sheet’s US FDA Performance Tracker.
Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
- Specialty Pharmaceuticals
- Controlled Release
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.